Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach
Following a rough few weeks, the revolving door at the executive suite to Immunomedics $IMMU is turning once more.
After the market closed on Monday the company put out word that CEO Michael Pehl has decided to leave for personal reasons. His abrupt exit after 15 months on the job comes a little more than a month after the FDA handed the company a CRL for its application to market the antibody drug conjugate IMMU-132, or sacituzumab govitecan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.